The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II pilot study of the efficacy and safety of nivolumab and ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgical treatment.
 
Ilya Tsimafeyeu
Leadership - Ruspharmtech
Stock and Other Ownership Interests - Ruspharmtech
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Ruspharmtech
Research Funding - Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Kidney Cancer Research Bureau; Oncomax LLC; Ruspharmtech
 
Maria Volkova
No Relationships to Disclose
 
Rustem Airatovich Gafanov
No Relationships to Disclose
 
Dmitry Nosov
No Relationships to Disclose
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)